• Rotigotine Workflows for Parkinson’s Disease Research

  2026-09-03

  Rotigotine supports receptor-focused cell assays, Parkinson’s disease models, and depression-related behavioral studies in one adaptable workflow. This guide translates dose-response findings into practical controls, delivery strategies, and troubleshooting steps that help separate genuine dopaminergic effects from locomotor confounding.

• Bobcat339: TET Inhibition Meets Bone Epigenetics

  2026-09-03

  A translational framework for using Bobcat339 to interrogate TET1/TET2 biology, DNA methylation regulation, and the UHRF1–super-enhancer–TGM2 axis implicated in senile osteoporosis.

• Captopril: From ACE Inhibition to Assay Design

  2026-09-02

  Captopril is an ACE inhibitor with a well-defined cardiovascular mechanism and valuable applications in hypertension research. This article presents an assay-centered framework linking ACE activity, bradykinin B2 signaling, intestinal motility, and oncology evidence without overstating translational conclusions.

• KN-62 and the Next Logic of Calcium Signaling

  2026-09-02

  A translational perspective on KN-62 as a CaMKII-focused research tool, linking calcium signaling, secretion, metabolism, cell-cycle control, and emerging calcium-dependent autophagy biology while distinguishing established evidence from testable hypotheses.

• Captopril, ACE, and Bradykinin Assay Design

  2026-09-01

  Captopril is an ACE inhibitor whose effects extend beyond angiotensin signaling into bradykinin biology. This article translates guinea pig ileum findings into a rigorous framework for designing and interpreting tissue-reflex assays without overextending the evidence.

• GSTA1, Glutathione Loss, and α-Amanitin Hepatotoxicity

  2026-09-01

  The reference study identifies GSTA1 as an unexpected driver of α-amanitin-induced liver injury rather than solely a protective detoxification enzyme. By combining mouse toxicology, multi-omics, binding assays, and genetic intervention, it links NRF2-associated GSTA1 induction to glutathione depletion, reactive oxygen species accumulation, and hepatocyte death.

• Tubastatin A: HDAC6 Inhibitor Workflows

  2026-08-31

  Tubastatin A combines strong HDAC6 selectivity with a practical pharmacodynamic readout: α-tubulin hyperacetylation. This guide translates cardiac ischemia–reperfusion findings into reproducible workflows for cancer biology, inflammation, neuroprotection, and cell-death studies.

• Bifendate, Autophagy, and Lipid Accumulation

  2026-08-31

  The reference study shows that bifendate inhibits autophagy at several functionally distinct stages, including autophagosome–lysosome fusion, lysosomal acidification, and autophagic lysosome reformation. It also reports reduced oleic acid-induced lipid droplet accumulation, providing a mechanistic framework for investigating how bifendate may influence hepatic lipid handling.

• SB203580 in Oral–Lung Inflammation Research

  2026-08-30

  SB203580 is a powerful tool for p38 MAPK signaling pathway research. This article explains how to use it to dissect the oral–lung inflammatory axis, interpret pathway readouts, and design stronger epithelial–neutrophil assays.

• TAI-1 Hec1 Inhibitor Workflows for Cancer Research

  2026-08-29

  TAI-1 enables mechanism-led studies of Hec1-Nek2 disruption, mitotic misalignment, and apoptotic cell death induction rather than relying on viability data alone. This practical guide connects nanomolar cell assays with combination testing, genotype-aware design, and carefully bounded hypotheses around replication stress.

• A 83-01: ALK-5 Inhibitor for TGF-β Research

  2026-08-28

  A 83-01 is a selective ALK-5 inhibitor that blocks TGF-β-driven Smad-dependent transcription in biochemical and cellular research assays. Its defined potency, receptor profile, solubility limitations, and relevance to organoid workflows make it useful for controlled TGF-β signaling pathway inhibitor studies, but not a substitute for direct validation in every model.

• Pifithrin-α: Decoding p53 in Ferroptosis

  2026-08-28

  Explore how Pifithrin-α, a p53 inhibitor, can distinguish p53-driven ferroptosis from correlated stress responses in environmental neurotoxicity models. This evidence-focused guide translates a recent deltamethrin study into practical assay design, controls, and interpretation strategies.

• Angiotensin I: From Precursor to Translational Signal

  2026-08-27

  A thought-leadership guide to using Angiotensin I as a mechanistically resolved perturbation in renin-angiotensin system research, cardiovascular disease mechanisms, neuroendocrine studies, and antihypertensive drug screening.

• PROTAC Nanoassemblies Sensitize FLASH Radiotherapy

  2026-08-27

  The reference study develops a folate-targeted, redox-responsive PROTAC nanoassembly that releases ARV-771 to degrade BRD4 and improve FLASH radiotherapy in resistant tumors. Its findings connect targeted protein degradation with impaired DNA repair, increased oxidative stress, and enhanced apoptotic and necrotic tumor-cell killing.

• Dual HER2–VEGFR2 Targeting in TNBC

  2026-08-26

  The reference study evaluates lapatinib plus Telatinib (BAY 57-9352) in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Its central finding is that individual and combined tyrosine kinase inhibition reduced proliferation, invadopodia formation, and 2D angiogenesis tube formation, while the in vitro design leaves questions about target engagement, synergy, and in vivo relevance.

7928 records 1/529 page Next 12345 下5页 Last page